CLOs on the Move

Bausch Health

www.bauschhealth.com

 
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 7,000 employees are united around our mission of improving people`s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries. Five pillars, or guiding principles, represent the foundation on which we are realizing our mission ...
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion
  • www.bauschhealth.com
  • 400 Somerset Corporate Boulevard
    Bridgewater, NJ USA 08807
  • Phone: 800.553.5340

Executives

Name Title Contact Details
Seana Carson
 Executive Vice President and General Counsel Profile
Rafael Gonzalez
 Sr. Global Head Ethics and Compliance Operations (Sr. Director) Profile
Kwame Obeng
 Vice President, Regulatory Affairs -CMC Profile
Lee Evans
 Vice President and Global Head of Regulatory Affairs Profile
David Alexander
 Chief Ethics and Compliance Officer Profile

Similar Companies

Pearl Health Clinic

Pearl Health Clinic provides unparalleled treatment to the community of Eastern Idaho and surrounding areas.

Chromocell, Corporation

Chromocell, Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinuvel

Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Laboratories

Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.